Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941849 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report.
SAGE Open Med Case Rep
January 2025
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Hidradenitis suppurativa is a chronic inflammatory disease of the skin with a suppurative-cicatricial outcome affecting the infundibular component of the pilo-sebaceous unit. The lesions are typically localized in the intertriginous and apocrine gland-rich areas. Hidradenitis suppurativa mainly affects patients at a young age and is very often refractory to conventional medical treatment.
View Article and Find Full Text PDFNorth American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations.
J Am Acad Dermatol
December 2024
Department of Dermatology, University of California, San Francisco, California.
Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.
Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease.
Australasian hidradenitis suppurativa management guidelines.
Australas J Dermatol
November 2024
Fremantle Dermatology, Fremantle, Western Australia, Australia.
Hidradenitis Suppurativa is a burdensome inflammatory skin disease with significant quality of life impact. These management guidelines were developed to direct appropriate clinical management in the Australasian context. A systematic review was used for the basis of the consensus guidelines.
View Article and Find Full Text PDFClinical Features and Natural Course of Hidradenitis Suppurativa in Turkey: A Multicenter Study.
Dermatology
November 2024
Department of Dermatology and Venereology, Faculty of Medicine, Akdeniz University, Antalya, Turkey,
Introduction: The natural history, the progression of a disease process in an individual over time, has not yet been fully elucidated in hidradenitis suppurativa (HS). In this large multicenter study, we aimed to investigate the natural history of HS and its gender differences.
Methods: This cross-sectional study included 827 patients.
Hidradenitis Suppurativa and Maternal and Offspring Outcomes.
JAMA Dermatol
December 2024
Institut national de santé publique du Québec, Montreal, Quebec, Canada.
Importance: Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.
Objective: To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.
Design, Setting, And Participants: This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!